Acumen Pharmaceuticals
(NASDAQ:ABOS)
$3.39
0.23[7.28%]
At close: Apr 24
$3.39
0[0.00%]
After Hours: 4:12PM EDT
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary

Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.

Open$3.120
Close$3.180
Volume / Avg.152.249K / 344.275K
Day Range3.105 - 3.210
52 Wk Range1.810 - 11.310
Market Cap$203.670M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
42
Short Interest
2.77%
Days to Cover2.59

Recent News

Sponsored
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™ cellular drug in the next 3 to 4 months.
$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Tuesday, there were a few notable insider trades.
Lisa Levin
Sponsored
Neuroinflammation A Key Indicator For Alzheimer's, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
There have been several accelerated approvals granted to treatments for patients with Alzheimer’s disease (AD) by the Food and Drug Administration (FDA) in recent months, and there are several treatments also in development.
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Dec 23
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
About Acumen Pharmaceuticals Inc
Sector
Health Care
Industry
Biotechnology
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
ABOS
OTLK

FAQ

Q

How do I buy Acumen Pharmaceuticals (ABOS) stock?

A

You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Acumen Pharmaceuticals's (ABOS) competitors?

A

Other companies in Acumen Pharmaceuticals’s space includes: Outlook Therapeutics (NASDAQ:OTLK), Innate Pharma (NASDAQ:IPHA), Galectin Therapeutics (NASDAQ:GALT), bluebird bio (NASDAQ:BLUE) and Atossa Therapeutics (NASDAQ:ATOS).

Q

What is the target price for Acumen Pharmaceuticals (ABOS) stock?

A

The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by HC Wainwright & Co. on Wednesday, March 27, 2024. The analyst firm set a price target for 15.00 expecting ABOS to rise to within 12 months (a possible 342.48% upside). 8 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Acumen Pharmaceuticals (ABOS)?

A

The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $3.39 last updated April 24, 2024 at 4:12 PM EDT.

Q

Does Acumen Pharmaceuticals (ABOS) pay a dividend?

A

There are no upcoming dividends for Acumen Pharmaceuticals.

Q

When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?

A

Acumen Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 7, 2024.

Q

Is Acumen Pharmaceuticals (ABOS) going to split?

A

There is no upcoming split for Acumen Pharmaceuticals.

Q

What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?

A

Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch